Nexalis Therapeutics Ltd

NX1.ASX

Health Care

Australian clinical stage drug development company that is developing rapid onset therapies to address unmet medical needs in pain management and mental health sectors.

Market Data

Price

$0.023

-0.0%
Market Cap

$5.8M

P/E Ratio

-100000.0x

EPS

$-0.007

Div. Yield

0.00%

52-Week Change

-0.3%

Latest Earnings

Preliminary Final Report

27 February 2026

NPAT
-$1.83
-51.3% YoY
EPS
$-0.01

Nexalis Therapeutics (formerly InhaleRx) reported a net loss of $1.83M for FY2025, a 51.3% deterioration from $1.21M loss in FY2024, driven by nearly tripled product development expenditure ($1.76M vs $0.62M) as the company invests heavily in pipeline advancement. The company remains in a net liability position of $1.18M but raised $0.54M in capital during the year and received $0.76M in R&D tax offsets, funding ongoing operations with cash increasing to $0.44M. Key points: R&D tax offset of $0.76M received, providing critical funding support for development activities; Successfully raised $0.54M in share capital during the year, demonstrating investor support for pipeline development; Cash position improved to $0.44M (up from $0.19M) through financing activities despite operational cash burn

Recent Announcements

27 Feb 2026 Actual Results Negative

Preliminary Final Report

Nexalis Therapeutics (formerly InhaleRx) reported a net loss of $1.83M for FY2025, a 51.3% deterioration from $1.21M loss in FY2024, driven by nearly tripled product development expenditure ($1.76M vs $0.62M) as the company invests heavily in pipeline advancement. The company remains in a net liability position of $1.18M but raised $0.54M in capital during the year and received $0.76M in R&D tax offsets, funding ongoing operations with cash increasing to $0.44M. Key points: R&D tax offset of $0.76M received, providing critical funding support for development activities; Successfully raised $0.54M in share capital during the year, demonstrating investor support for pipeline development; Cash position improved to $0.44M (up from $0.19M) through financing activities despite operational cash burn

Get real-time alerts for NX1

Receive AI-powered earnings summaries and instant notifications when Nexalis Therapeutics Ltd releases results.

Register Free